Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and challenges

Pharmacology and Therapeutics

Volumn 177, Issue , 2017, Pages 56-66

  Hattori, Yuichi ^a   Hattori, Kohshi ^b   Suzuki, Tokiko ^a   Matsuda, Naoyuki ^c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Endothelial cells; Inflammation; Organ dysfunction; Sepsis

Indexed keywords

ADENOSINE; ANTIOXIDANT; CHLOROQUINE; CYTOKINE; ETHYL PYRUVATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEVOSIMENDAN; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CELL ACTIVATION; HUMAN; IMMUNE RESPONSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; VASCULAR ENDOTHELIAL CELL; ANIMAL; COMPLICATION; ENDOTHELIUM CELL; IMMUNOLOGY; METABOLISM;

ANIMALS; APOPTOSIS; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; MULTIPLE ORGAN FAILURE; NF-KAPPA B; SEPSIS;

EID: 85014376153     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.02.040     Document Type: Review

References (193)

1. Abraham, E., Nuclear factor-κB and its role in sepsis-associated organ failure. The Journal of Infectious Diseases 187:Suppl. 2 (2003), S364–S369.
2. Abraham, E., Anzueto, A., Gutierrez, G., Tessler, G., San Pedro, G., Wunderink, R., Porter, S., Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet 351 (1998), 929–933.
3. Abraham, E., Laterre, P.F., Garbino, J., Pingleton, S., Butler, T., Dugernier, T., Lenercept Study Group, Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1342 patients. Critical Care Medicine 29 (2001), 503–510.
4. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., OPTIMIST Trial Study Group, Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 290 (2003), 238–247.
5. Aird, W.C., The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101 (2003), 3765–3777.
6. Ait-Oufella, H., Maury, E., Lehoux, S., Guidet, B., Offenstadt, G., The endothelium: Physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Medicine 36 (2010), 1286–1298.
7. Almong, Y., Shefer, A., Novack, V., Maimon, N., Barski, L., Eizinger, M., Danon, A., Prior statin therapy is associated with a decreased rate of sepsis. Circulation 110 (2004), 880–885.
8. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R., Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 29 (2001), 1303–1310.
9. Angus, D.C., van der Poll, T., Severe sepsis and septic shock. The New England Journal of Medicine 369 (2013), 840–851.
10. Annane, D., Sebille, V., Charpentier, C., Bollaert, P.E., Francois, B., Korach, J.M., Bellissant, E., Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002), 862–871.
11. Ayala, A., Herdon, C.D., Lehman, D.L., Ayala, C.A., Chaudry, I.H., Differential induction of apoptosis in lymphoid tissues during sepsis: Variation in onset, frequency, and the nature of the mediators. Blood 87 (1996), 4261–4275.
12. Badger, A.M., Olivera, D.L., Esser, K.M., Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxyfylline, and rolipram in a murine model of endotoxin shock. Circulatory Shock 44 (1994), 188–195.
13. Baer, C., Squadrito, M.L., Iruela-Arispe, M.L., DePalma, M., Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. Experimental Cell Research 319 (2013), 1626–1634.
14. Baldwin, A.S. Jr., The NF-κB and IκB proteins: New discoveries and insights. Annual Review of Immunology 14 (1996), 649–683.
15. Bannermann, D.D., Sathyamoorthy, M., Goldblum, S.E., Bacterial lipopolysaccharide disrupts endothelial monolayer integrity and survival signaling events through caspase cleavage of adherens junction proteins. The Journal of Biological Chemistry 273 (1998), 35371–35380.
16. Bäuerle, P.A., Baltimore, D., NF-κB: Ten years after. Cell 87 (1996), 13–20.
17. Beghè, B., Rabe, K.F., Fabbri, L.M., Phosphodiesterase-4 inhibitor therapy for lung diseases. American Journal of Respiratory and Critical Care Medicine 188 (2013), 271–278.
18. Bender, A.T., Beavo, J.A., Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacological Reviews 58 (2006), 488–520.
19. Blackwell, T.S., Christman, J.W., Sepsis and cytokines: Current status. British Journal of Anaesthesia 77 (1996), 110–117.
20. Boatright, K.M., Salvesen, G.S., Mechanisms of caspase activation. Current Opinion in Cell Biology 15 (2003), 725–731.
21. Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., Sibbald, W.J., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. ACCP/SCCM consensus committee, American College of Chest Physician/Society of Critical Care Medicine. Chest 101 (1992), 1644–1655.
22. Brown, W.M., Treating COPD with PDE4 inhibitors. International Journal of Chronic Obstructive Pulmonary Disease 2 (2007), 517–533.
23. Buenestado, A., Grassin-Delyle, S., Guitard, F., Naline, E., Faisy, C., Israël-Biet, D., Devillier, P., Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. British Journal of Pharmacology 165 (2012), 1877–1890.
24. Caserta, T.M., Smith, A.N., Gultice, A.D., Reedy, M.A., Brown, T.L., Q-VD-Oph, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8 (2003), 345–352.
25. Chopra, M., Reuben, J.S., Sharma, A.C., Acute lung injury: Apoptosis and signaling mechanisms. Experimental Biology and Medicine 234 (2009), 361–371.
26. Cines, D.B., Pollak, E.S., Buck, C.A., Loscalzo, J., Zimmerman, G.A., McEver, R.P., Stern, D.M., Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998), 3527–3561.
27. Coldewey, S.M., Rogazzo, M., Collino, M., Patel, N.S., Thiemermann, C., Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. Disease Models & Mechanisms 6 (2013), 1031–1042.
28. Collins, T., Endothelial nuclear factor-kappa B and the initiation of atherosclerotic lesion. Laboratory Investigation 68 (1993), 499–508.
29. Collins, T., Read, M.A., Neish, A.S., Whitley, M.Z., Thanos, D., Maniatis, T., Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. The FASEB Journal 9 (1995), 899–909.
30. Coopersmith, C.M., Chang, K.C., Swanson, P.E., Tinsley, K.W., Stromberg, P.E., Buchman, T.G., Hotchkiss, R.S., Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Critical Care Medicine 30 (2002), 195–201.
31. Coopersmith, C.M., Stromberg, P.E., Dunne, W.M., Davis, C.G., Amiot, D.M., Buchman, T.G., Hotchkiss, R.S., Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 287 (2002), 1716–1721.
32. Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F., New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacology & Therapeutics 84 (1999), 413–428.
33. Court, O., Kumar, A., Parrillo, J.E., Kumar, A., Clinical review: Myocardial depression in sepsis and septic shock. Critical Care 6 (2002), 500–508.
34. 2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. Journal of Immunology 185 (2010), 542–550.
35. Davis, R.P., Miller-Dorey, S., Jenne, C.N., Platelets and coagulation in infection. Clinical and Translational Immunology, 5, 2016, e89.
36. De Backer, D., Orbegozo Cortes, D., Donadello, K., Vincent, J.L., Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence 5 (2014), 73–79.
37. Deanfield, J.E., Halcox, J.P., Rabelink, T.J., Endothelial function and dysfunction: Testing and clinical relevance. Circulation 115 (2007), 1285–1295.
38. Deutchman, C.S., Tracey, K.J., Sepsis: Current dogma and new perspectives. Immunity 40 (2014), 463–475.
39. Edul, V.S., Enrico, C., Laviolle, B., Vazquez, A.R., Ince, C., Dubin, A., Quantitative assessment of the microcirculation in healthy volunteers and in patients with septic shock. Critical Care Medicine 40 (2012), 1443–1448.
40. 2 + sesitizers. Circulation Journal 72 (2008), 1915–1925.
41. Ertel, W., Morrison, M.H., Ayala, A., Chaudry, J.H., Chloroquine attenuates hemorrhagic shock-induced immunosuppression and decreases susceptibility to sepsis. Archives of Surgery 127 (1992), 70–75 (discussion 75-76).
42. Fang, H., Liu, A., Dirsch, O., Dual role of chloroquine in liver ischemia reperfusion injury: Reduction of liver damage in early phase, but aggravation in late phase. Cell Death & Disease, 4, 2013, e694.
43. Fink, M.P., Ethyl pyruvate: A novel anti-inflammatory agent. Journal of Internal Medicine 261 (2007), 349–362.
44. Fisher, C.J. Jr., Dhainaut, J.F., Opal, S.M., Pribble, J.P., Balk, R.A., Slotman, G.J., Iberti, T.J., Rackow, E.C., Shapiro, M.J., Greenman, R.L., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra sepsis syndrome study group. JAMA 271 (1994), 1836–1843.
45. Flemming, S., Schlegel, N., Wunder, C., Meir, M., Baar, W., Wollborn, J., Schick, M.A., Phosphodiesterase 4 inhibition does dependently stabilizes microvascular barrier functions and microcirculation in a rodent model of polymicrobial sepsis. Shock 41 (2014), 537–545.
46. Foletta, V.C., Segal, D.H., Cohen, D.R., Regulation in the immune system: All roads lead to AP-1. Journal of Leukocyte Biology 63 (1998), 139–152.
47. Folkesson, H.G., Kuzenko, S.R., Lipson, D.A., Matthay, M.A., The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats. American Journal of Physiology. Lung Cellular and Molecular Physiology 303 (2012), LL259–LL271.
48. Fox, R.I., Mechanism of action of hydroxycholoroquine as an antirheumatic drug. Seminars in Arthritis and Rheumatism 23 (1993), 82–91.
49. Frey, E.A., Finlay, B.B., Lipopolysaccharide induces apoptosis in a bovine endothelial cell line via a soluble CD14-dependent pathway. Microbial Pathogenesis 24 (1998), 101–109.
50. Frishman, W.H., Advances in positive inotropic therapy: Levosimendan. Critical Care Medicine 31 (2003), 2408–2409.
51. Gallos, G., Ruyle, T.D., Emala, C.W., Lee, H.T., A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis. American Journal of Physiology. Renal Physiology 289 (2005), F369–F376.
52. Gill, S.E., Rohan, M., Mehta, S., Role of pulmonary microvascular endothelial cell apoptosis in murine sepsis-induced lung injury in vivo. Respiratory Research, 16, 2015, 109.
53. Gilmore, T.D., Introduction to NF-κB: Players, pathways, perspective. Oncogene 25 (2006), 6680–6684.
54. Goldenberg, N.M., Steinberg, B.E., Slutsky, A.S., Lee, W.L., Broken barriers: A new take on sepsis pathogenesis. Science Translational Medicine, 3, 2011, 88ps25.
55. Goldstein, J.L., Brown, M.S., The LDL receptor. Arteriosclerosis, Thrombosis, and Vascular Biology 29 (2009), 431–438.
56. Gordon, A.C., Perkins, G.D., Singer, M., McAuley, D.F., Orme, R.M.L., Santhakumaran, S., Ashby, D., Levosimendan for prevention of acute organ dysfunction in sepsis. The New England Journal of Medicine 375 (2016), 1638–1648.
57. Greenwood, J., Mason, J.C., Statins and the vascular endothelial inflammatory response. Trends in Immunology 28 (2007), 88–98.
58. Gupta, R., Plantinga, L.C., Melamed, M.L., Coresh, J., Fox, C.S., Levin, N.W., Powe, N.R., Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA 297 (2007), 1455–1464.
59. Haskó, G., Csóka, B., Koscsó, B., Chandra, R., Pacher, P., Thompson, L.F., Németh, Z.H., Ecto-5′-nucleotidase (CD73) decreases mortality and organ injury in sepsis. Journal of Immunology 187 (2011), 4256–4267.
60. Haskó, G., Németh, Z.H., Vizi, E.S., Salzman, A.W., Szabó, C., An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. European Journal of Pharmacology 358 (1998), 261–268.
61. Haskó, G., Szabó, C., Németh, Z.H., Salzman, A.L., Vizi, E.S., Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent. European Journal of Immunology 23 (1998), 468–472.
62. Haslinger-Löffler, B., Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function. Kidney International 74 (2008), 553–555.
63. Hattori, M., Yamazaki, M., Ohashi, W., Tanaka, S., Hattori, K., Todoroki, K., Hattori, Y., Critical role of endogenous histamine in promoting end-organ tissue injury in sepsis. Intensive Care Medicine Experimental, 4, 2016, 36.
64. Hattori, Y., Takano, K., Teramae, H., Yamamoto, S., Yokoo, H., Matsuda, N., Insights into sepsis therapeutic design based on the apoptotic death pathway. Journal of Pharmacological Sciences 114 (2010), 354–365.
65. Hayden, M.S., Ghosh, S., Signaling to NF-κB. Genes & Development 18 (2004), 2195–2224.
66. Hollenbach, M., Hintersdorf, A., Huse, K., Sack, U., Bial, M., Groth, M., Birkenmeier, G., Ethyl pyruvate and ethyl lactate down-regulate the production of pro-inflammatory cytokines and modulate expression of immune receptors. Biochemical Pharmacology 76 (2008), 631–644.
67. Holthoff, J.H., Wang, Z., Patil, N.K., Gokden, N., Mayeux, P.R., Rolipram improves renal perfusion and function during sepsis in the mouse. The Journal of Pharmacology and Experimental Therapeutics 347 (2013), 357–364.
68. Hong, Z., Jiang, Z., Liangxi, W., Guofu, D., Ping, L., Yongling, L., Minghai, W., Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. International Immunopharmacology 4 (2004), 223–234.
69. Hotchkiss, R.S., Swanson, P.E., Cobb, J.P., Jacobson, A., Buchman, T.G., Karl, I.E., Apoptosis in lymphoid and parenchymal cells during sepsis: Findings in normal and T- and B-cell-deficient mice. Critical Care Medicine 25 (1997), 1298–1307.
70. Hotchkiss, R.S., Swanson, P.E., Freeman, B.D., Tinsley, K.W., Cobb, J.P., Matuschak, G.M., Karl, I.E., Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Critical Care Medicine 27 (1999), 1230–1251.
71. Hotchkiss, R.S., Swanson, P.E., Knudson, C.M., Chang, K.C., Cobb, J.P., Osborne, D.F., Karl, I.E., Overexpression of Bcl-2 decreases apoptosis and improves survival in sepsis. Journal of Immunology 162 (1999), 4148–4156.
72. Hotchkiss, R.S., Tinsley, K.W., Swanson, P.E., Chang, K.C., Cobb, J.P., Buchman, T.G., Karl, I.E., Prevention of lymphocyte cell death in sepsis improves survival in mice. Proceedings of the National Academy of Sciences of the United States of America 96 (1999), 14541–14546.
73. Hoyt, D.G., Mannix, R.J., Rusnak, J.M., Pitt, B.R., Lazo, J.S., Collagen is a survival factor against LPS-induced apoptosis in cultured sheep pulmonary artery endothelial cells. The American Journal of Physiology 269 (1995), L171–L177.
74. Jacobson, K.A., Adenosine A3 receptors: Novel ligands and paradoxical effects. Trends in Pharmacological Sciences 19 (1998), 184–191.
75. Jacobson, J.R., Barnard, J.W., Grigoryev, D.N., Ma, S.F., Tuder, R.M., Garcia, J.G., Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 288 (2005), L1026–L1032.
76. Jobin, C., Bradham, C.A., Russo, M.P., Juma, B., Narula, A.S., Brenner, D.A., Sartor, R.B., Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor IκB kinase activity. Journal of Immunology 1163 (1999), 3474–3483.
77. Kamiyama, K., Matsuda, N., Yamamoto, S., Takano, K., Takano, Y., Yamazaki, H., Hattori, Y., Modulation of glucocorticoid receptor expression, inflammation, and cell apoptosis in septic Guinea pig lungs using methylprednisolone. American Journal of Physiology. Lung Cellular and Molecular Physiology 295 (2008), L998–L1006.
78. Karin, M., Liu, Z., Zandi, E., AP-1 function and regulation. Current Opinion in Cell Biology 9 (1997), 240–246.
79. Karres, I., Kremer, J.P., Dietl, I., Steckholzer, U., Jochum, M., Ertel, W., Chloroquine inhibits proinflammatory cytokine release into human whole blood. The American Journal of Physiology 274 (1998), R1058–R1064.
80. Kass, D.A., Solaro, R.J., Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113 (2006), 305–315.
81. Kawasaki, M., Kuwano, K., Hagimoto, N., Matsuba, T., Kunitake, R., Tanaka, T., Hara, N., Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. The American Journal of Pathology 157 (2000), 597–603.
82. 2A receptors in human monocytic THP-1 cells. Journal of Immunology 167 (2001), 4026–4032.
83. Koike, T., Nadeen Qutab, M., Tsuchida, M., Takekubo, M., Saito, M., Hayashi, J., Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulmonary Pharmacology & Therapeutics 21 (2008), 166–171 (2008).
84. Koshi, R., Methan, V.I., David, S., Mathan, M.M., Enteric vascular endothelial response to bacterial endotoxin. International Journal of Experimental Pathology 74 (1993), 593–601.
85. Kwak, B.R., Mulhaupt, F., Mach, F., Atherosclerosis: Anti-inflammatory and immunomodulatory activities of statins. Autoimmunity Reviews 2 (2003), 332–338.
86. 3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling. Immunobiology 216 (2011), 997–1003.
87. Lee, H.T., Kim, M., Joo, J.D., Gallos, G., Chen, J.F., Emala, C.W., A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 291 (2006), R959–R969.
88. Lee, W.L., Slutsky, A.S., Sepsis and endothelial permeability. The New England Journal of Medicine 363 (2010), 689–691.
89. Leelahavanichkul, A., Yasuda, H., Doi, K., Hu, X., Zhou, H., Yuen, P.S., Star, R.A., Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases sepsis-induced acute kidney injury in mice. American Journal of Physiology. Renal Physiology 295 (2008), F1825–F1835.
90. Lefering, R., Neugebauer, E.A., Steroid controversy in sepsis and septic shock: A meta-analysis. Critical Care Medicine 23 (1995), 1294–1303.
91. Levi, M., van der Poll, T., Inflammation and coagulation. Critical Care Medicine 38:2 Suppl (2010), S26–S34.
92. Levi, M., van der Poll, T., Endothelial injury in sepsis. Intensive Care Medicine 39 (2013), 1839–1842.
93. Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., for the International Sepsis Definitions Conference, 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Medicine 29 (2003), 530–538.
94. Ley, K., Laudanna, C., Cybulsky, M.I., Nourshargh, S., Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nature Reviews. Immunology 7 (2007), 678–689.
95. Li, Z.W., Chu, W., Hu, Y., Delhare, M., Deerinck, T., Ellisman, M., Karin, M., The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. The Journal of Experimental Medicine 189 (1999), 1839–1845.
96. Libermann, T.A., Baltimore, D., Activation of interleukin-6 gene expression through the NF-κB transcription factor. Molecular and Cellular Biology 10 (1990), 2327–2334.
97. Liu, S.F., Malik, A.B., NF-κB activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology 290 (2006), L622–L645.
98. Liu, S.F., Ye, X., Malik, A.B., Inhibition of NF-κB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100 (1999), 1330–1337.
99. Lugnier, C., Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacology & Therapeutics 109 (2006), 366–398.
100. Marshall, J.C., Clinical trials of mediator-directed therapy in sepsis: What have we learned?. Intensive Care Medicine 26 (2000), S75–S83.
101. Marshall, J.C., Cook, D.J., Christou, N.V., Bernard, G.R., Sprung, C.L., Sibbald, W.J., Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Critical Care Medicine 23 (1995), 1638–1652.
102. Martinod, K., Wagner, D.D., Thrombosis: Tangled up in NETs. Blood 123 (2014), 2768–2776.
103. Matejovic, M., Krouzecky, A., Radej, J., Novak, I., Successful reversal of resistant hypodynamic septic shock with levosimendan. Acta Anaesthesiologica Scandinavica 49 (2005), 127–128.
104. Mathiak, G., Szewczyk, D., Abdullah, F., Ovadia, P., Rabinovici, R., Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 7 (1997), 391–404.
105. Matsuda, N., Hattori, Y., Systemic inflammatory response syndrome (SIRS): Molecular pathophysiology and gene therapy. Journal of Pharmacological Sciences 101 (2006), 189–198.
106. Matsuda, N., Hattori, Y., Vascular biology in sepsis: Pathophysiological and therapeutic significance of vascular dysfunction. Journal of Smooth Muscle Research 43 (2007), 117–137.
107. Matsuda, N., Hattori, Y., Jesmin, S., Gando, S., Nuclear factor-κB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Molecular Pharmacology 67 (2005), 1018–1025.
108. Matsuda, N., Hattori, Y., Takahashi, Y., Nishihira, J., Jesmin, S., Kobayashi, M., Gando, S., Therapeutic effect of in vivo transfection of transcription factor decoy to NF-κB on septic lung in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 287 (2004), L1248–L1255.
109. Matsuda, N., Hayashi, Y., Takahashi, Y., Hattori, Y., Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: Reversal effect of fluvastatin therapy. The Journal of Pharmacology and Experimental Therapeutics 319 (2006), 1348–1354.
110. Matsuda, N., Takano, Y., Kageyama, S., Hatakeyama, N., Shakunaga, K., Kitajima, I., Hattori, Y., Silencing of caspase-8 and caspase-3 by RNA interference prevents vascular endothelial cell injury in mice with endotoxic shock. Cardiovascular Research 76 (2007), 132–140.
111. 4 receptors contributes to spleen apoptosis in septic mice: Counteraction of the antiapoptotic action of nuclear factor-κB. The Journal of Pharmacology and Experimental Therapeutics 332 (2010), 730–737.
112. Matsuda, N., Yamamoto, S., Takano, K., Kageyama, S., Kurobe, Y., Yoshimura, Y., Hattori, Y., Silencing of Fas-associated death domain protects mice from septic lung inflammation and apoptosis. American Journal of Respiratory and Critical Care Medicine 179 (2009), 806–815.
113. Matsuda, N., Yamamoto, S., Yokoo, H., Tobe, K., Hattori, Y., Nuclear factor-κB decoy oligodeoxynucleotides ameliorate impaired glucose tolerance and insulin resistance in mice with cecal ligation and puncture-induced sepsis. Critical Care Medicine 37 (2009), 2791–2799.
114. McCuskey, R.S., Urbaschek, R., Urbaschek, B., The microcirculation during endotoxemia. Cardiovascular Research 32 (1996), 752–763.
115. 1 receptors and the cardiovascular system: Regulation of expression and function. Cardiovascular Research 48 (2000), 194–210.
116. Merx, M.W., Liehn, E.A., Janssens, U., Lüticken, R., Schrader, J., Hanrath, P., Weber, C., HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109 (2004), 2560–2565.
117. Méthot, N., Huang, J.Q., Coulombe, N., Vaillancourt, J.P., Rasper, D., Tam, J., Roy, S., Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics. The Journal of Experimental Medicine 199 (2004), 199–207.
118. Meyrick, B., Pathology of the adult respiratory distress syndrome. Critical Care Clinics 2 (1986), 405–428.
119. Meyrick, B.O., Endotoxin-induced pulmonary endothelial cell injury. Federation Proceedings 45 (1986), 19–24.
120. Miyaji, T., Hu, X., Yuen, P.S.T., Muramatsu, Y., Iyer, S., Hewitt, S.M., Star, R.A., Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney International 64 (2003), 1620–1631.
121. Mizushige, K., Ueda, T., Yukiiri, K., Suzuki, H., Olprinone: A phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovascular Drug Reviews 20 (2002), 163–174.
122. Montrucchio, G., Alloatti, G., Camussi, G., Role of platelet-activating factor in cardiovascular pathophysiology. Physiological Reviews 80 (2000), 1669–1699.
123. Morelli, A., De Castro, S., Teboul, J.L., Singer, M., Rocco, M., Conti, G., Pietropaoli, P., Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Medicine 31 (2005), 638–644.
124. Morishita, R., Sugimoto, T., Aoki, M., Kita, I., Tomita, N., Moriguchi, A., Ogihara, T., In vivo transfection of cis element “decoy” against nuclear factor-κB binding site prevents myocardial infarction. Nature Medicine 3 (1997), 894–899.
125. Muller, W.A., Mechanisms of leukocyte transendothelial migration. Annual Review of Pathology 6 (2011), 323–344.
126. Mutunga, M., Fulton, B., Bullock, R., Batchelor, A., Gascoigne, A., Gillespie, J.I., Baudouin, S.V., Circulating endothelial cells in patients with septic shock. American Journal of Respiratory and Critical Care Medicine 163 (2001), 195–200.
127. Natanson, C., Esposito, C.J., Banks, S.M., The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error. Critical Care Medicine 26 (1998), 1927–1931.
128. Nathens, A.B., Bitar, R., Davreux, C., Bujard, M., Marshall, J.C., Dackiw, A.P.B., Rotstein, O.D., Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury. American Journal of Respiratory Cell and Molecular Biology 17 (1997), 608–616.
129. Neely, C.F., Jin, J., Keith, I.M., A1-adenosine receptor antagonists block endotoxin-induced lung injury. The American Journal of Physiology 272 (1997), L353–L361.
130. Netherton, S.J., Maurice, D.H., Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: Implications in angiogenesis. Molecular Pharmacology 67 (2005), 263–272.
131. Nimah, M., Brilli, R.J., Coagulation dysfunction in sepsis and multiple organ system failure. Critical Care Clinics 19 (2003), 441–458.
132. Oishi, H., Takano, K., Tomita, K., Takebe, M., Yokoo, H., Yamazaki, M., Hattori, Y., Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CRB-independent activation of the Akt pathway. American Journal of Physiology. Lung Cellular and Molecular Physiology 303 (2012), L130–L140.
133. Opal, S.M., Laterre, P.F., Francois, B., LaRosa, S.P., Angus, D.C., Mira, J.P., ACCESS Study Group, Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 309 (2013), 1154–1162.
134. Opal, S.M., van der Poll, T., Endothelial barrier dysfunction in septic shock. Journal of Internal Medicine 277 (2015), 277–293.
135. Oppenheim, J.J., Cytokines: Past, present, and future. International Journal of Hematology 74 (2001), 3–8.
136. Page, C.P., Spina, D., Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handbook of Experimental Pharmacology 204 (2011), 391–414.
137. Pahl, H.L., Activated and target genes of Rel/NF-κB transcription factors. Oncogene 18 (1999), 6853–6866.
138. Papp, Z., Csapó, K., Pollesello, P., Haikala, H., Edes, I., Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovascular Drug Reviews 23 (2005), 71–98.
139. Paraskevaidis, I.A., Parissis, J.T., Th Kremastinos, D., Anti-inflammatory and anti-apoptotic effects of levosimendan in decompesated heart failure: A novel mechanism of drug-induced improvement in contractile performance of the failing heart. Current Medicinal Chemistry. Cardiovascular and Hematological Agents 3 (2005), 243–247.
140. Parrillo, J.E., Parker, M.M., Natanson, C., Suffredini, A.F., Danner, R.L., Cunnion, R.E., Ognibene, F.P., Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Annals of Internal Medicine 113 (1990), 227–242.
141. Parrisis, J.T., Farmakis, D., Th Kremastinos, D., Anti-inflammatory effect of levosimendan in decompensated heart failure: Impact on weight loss and anemia. The American Journal of Cardiology 95 (2005), 923–924.
142. Perl, M., Chung, C.S., Lomas-Neira, J., Rachel, T.M., Biffl, W.L., Cioffi, W.G., Ayala, A., Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. The American Journal of Pathology 167 (2005), 1545–1559.
143. Perl, M., Chung, C.S., Perl, U., Lomas-Neira, J., de Paepe, M., Cioffi, W.G., Ayala, A., Fas-induced pulmonary apoptosis and inflammation during indirect acute lung injury. American Journal of Respiratory and Critical Care Medicine 176 (2007), 591–601.
144. Perl, M., Lomas-Neira, J., Venet, F., Chung, C.S., Ayala, A., Pathogenesis of indirect (secondary) acute lung injury. Expert Review of Respiratory Medicine 5 (2011), 115–126.
145. Rajapakse, N., Kim, M.M., Mendis, E., Kim, S.K., Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-κB signaling. Immunology 123 (2008), 348–357.
146. Ranieri, V.M., Thompson, B.T., Brie, P.S., Dhainaut, J.F., Douglas, I.S., Finfer, S., PROWESS-SHOCK Study Group, Drotrecogin alpha (activated) in adults with septic shock. The New England Journal of Medicine 336 (2012), 2055–2064.
147. Rinaldi, B., Donniacuo, M., Espoito, E., Capuano, A., Sodano, L., Mazzon, E., Rossi, F., PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. British Journal of Pharmacology 163 (2011), 609–623.
148. Rodrigues, S.F., Granger, D.N., Blood cells and endothelial barrier function. Tissue Barriers, 3, 2015, e978720.
149. Saffarzadeh, M., Juenemann, C., Queisser, M.A., Lochnit, G., Barreto, G., Galuska, S.P., Preissner, K.T., Neutrophil extracellular traps directly induce epithelial and endothelial cell death: A predominant role of histones. PLoS One, 7, 2012, e32366.
150. Sareila, O., Kornhonen, R., Auvinen, H., Hämäläinen, M., Kankaanranta, H., Nissinen, E., Moilanen, E., Effects of levo- and dextrosimendan on NF-κB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli. British Journal of Pharmacology 155 (2008), 884–895.
151. Schick, M.A., Wunder, C., Wollborn, J., Roewer, N., Waschke, J., Germer, C.T., Schlegel, N., Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation. The Journal of Physiology 590 (2012), 2693–2708.
152. Schingnitz, U., Hartmann, K., MacManus, C.F., Eckle, T., Zug, S., Colgan, S.P., Eltzschig, H.K., Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. Journal of Immunology 184 (2010), 5271–5279.
153. Schmidt, H., Siems, W.G., Grune, T., Grauel, E.L., Concentrations of purine compounds in the cerebrospinal fluid of infants suffering from sepsis, convulsions and hydrocephalus. Journal of Perinatal Medicine 23 (1995), 167–174.
154. Schurr, J.W., Wu, W., Smith-Hannah, A., Smith, C.J., Barrera, R., Incidence of sepsis and mortality with prior exposure of HMG-COA reductase inhibitors in a surgical intensive care population. Shock 45 (2016), 10–15.
155. Sekut, L., Yarnall, D., Stimpson, S.A., Noel, L.S., Bateman-Fite, R., Clark, R.L., Connolly, K.M., Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clinical and Experimental Immunology 100 (1995), 126–132.
156. Sena, C.M., Pereira, A.M., Seiça, R., Endothelial dysfunction – A major mediator of diabetic vascular disease. Biochimica et Biophysica Acta 1832 (2013), 2216–2231.
157. Sheehan, M., Wong, H.R., Hake, P.W., Halhotra, V., O'Connor, M., Zingarelli, B., Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Molecular Pharmacology 61 (2002), 953–963.
158. Simon, S.I., Goldsmith, H.L., Leukocyte adhesion dynamics in shear flow. Annals of Biomedical Engineering 30 (2002), 315–332.
159. Singer, S., Aggarwal, B.B., Activation of transcription factor NF-κB is suppressed by curcumin (diferuoylmethane). The Journal of Biological Chemistry 270 (1995), 24995–25000.
160. Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., Angus, D.C., The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315 (2016), 801–810.
161. Skibsted, S., Jones, A.E., Puskarich, M.A., Arnold, R., Sherwin, R., Trzeciak, S., Shapiro, N.I., Biomarkers of endothelial cell activation in early sepsis. Shock 39 (2013), 427–432.
162. Sprung, C.L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Briegel, J., Hydrocortisone therapy for patients with septic shock. The New England Journal of Medicine 358 (2008), 111–124.
163. Sun, C.X., Young, H.W., Molina, J.G., Volmer, J.B., Schnermann, J., Blackburn, M.R., A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. The Journal of Clinical Investigation 115 (2005), 35–43.
164. Sutton, E.T., Zhou, Z., Baker, C.H., Price, J.M., Chen, Y., Differences in arterial and arteriolar endothelial structure during endotoxin shock. Circulatory Shock 41 (1993), 71–76.
165. Takano, K., Yamamoto, S., Tomita, K., Takashina, M., Yokoo, H., Matsuda, N., Hattori, Y., Successful treatment of acute lung injury with pitavastatin in septic mice: Potential role of glucocorticoid receptor expression in alveolar macrophages. The Journal of Pharmacology and Experimental Therapeutics 336 (2011), 381–390.
166. Takebe, M., Oishi, H., Taguchi, K., Aoki, Y., Takashina, M., Tomita, K., Hattori, Y., Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis. The Journal of Surgical Research 187 (2014), 559–570.
167. Tao, C.M., Li, K.Y., Chen, S.J., Ka, S.M., Liaw, W.J., Huang, H.C., Wu, C.C., Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: Studies in a rat model. Critical Care, 18, 2014, 652.
168. Trede, N.S., Tsytsykova, A.V., Chatila, T., Goldfeld, A.E., Geha, R.S., Transcriptional activation of the human TNF-α promoter by superantigen in human monocytic cells: Role of NF-κB. Journal of Immunology 155 (1995), 902–908.
169. Ulloa, L., Ochani, M., Yang, H., Tanovic, M., Halperin, D., Yang, R., Tracey, K.J., Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proceedings of the National Academy of Sciences of the United States of America 99 (2002), 12351–12356.
170. Vallet, B., Wiel, E., Endothelial cell dysfunction and coagulation. Critical Care Medicine 29 (2001), S36–S41.
171. Van de Wouwer, M., Collen, D., Conway, E., Thrombomodulin-protein C-EPCR system. Arteriosclerosis, Thrombosis, and Vascular Biology 24 (2004), 1374–1383.
172. Van Noorden, C.J., The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochemica 103 (2001), 241–251.
173. Vieillard-Baron, A., Caille, V., Charron, C., Belliard, G., Page, B., Jardin, F., Actual incidence of global left ventricular hypokinesia in adult septic shock. Critical Care Medicine 36 (2008), 1701–1706.
174. Vincent, J.L., Steroids in sepsis: Another swing of the pendulum in our clinical trials. Critical Care, 12, 2008, 141.
175. Volk, T., Kox, W.J., Endothelium function in sepsis. Inflammation Research 49 (2000), 185–198.
176. Wallace, D.J., Antimalarial agents and lupus. Rheumatic Diseases Clinics of North America 20 (1994), 243–263.
177. Wang, H., Ma, S., The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. The American Journal of Emergency Medicine 26 (2008), 711–715.
178. Wang, H.E., Shapiro, N.I., Angus, D.C., Yealy, D.M., National estimates of severe sepsis in unites states emergency departments. Critical Care Medicine 35 (2007), 1928–1936.
179. Wang, Q., Yokoo, H., Takashina, M., Sakata, K., Ohashi, W., Abedelzaher, L.A., Hattori, Y., Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages. Critical Care Medicine 43 (2015), e508–e520.
180. Weber, P., Wang, P., Maddens, S., Wang, P.S., Wu, R., Miksa, M., Charlton, P., VX-166: A novel potent small molecule caspase inhibitor as a potential therapy for sepsis. Critical Care, 13, 2009, R146.
181. Wen, A.Y., Sakamoto, K.M., Miller, L.S., The role of the transcription factor CREB in immune function. Journal of Immunology 185 (2010), 6413–6419.
182. Wilson, C.N., Vance, C.O., Lechner, M.G., Matsuschak, G.M., Lechner, A.J., Adenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsis. European Journal of Pharmacology 740 (2014), 346–352.
183. 2B adenosine receptor expression in macrophages: A mechanism of macrophage deactivation. Journal of Immunology 162 (1999), 3607–3614.
184. Yang, M., Cao, L., Xie, M., Yu, Y., Kang, R., Yang, L., Tang, D., Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochemical Pharmacology 86 (2013), 410–418.
185. Yang, R., Gallo, D.J., Baust, J.J., Uchiyama, T., Watkins, S.K., Delude, R.L., Fink, M.P., Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. American Journal of Physiology. Gastrointestinal and Liver Physiology 283 (2002), G212–G221.
186. Yao, H.W., Mao, L.G., Zhu, J.P., Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clinical and Experimental Pharmacology & Physiology 33 (2006), 793–797.
187. Yasuda, H., Leelahavanichkul, A., Tsunoda, S., Dear, J.W., Takahashi, Y., Ito, S., Star, R.A., Chloroquine and inhibition of toll-like receptor 9 protect from sepsis-induced acute kidney injury. American Journal of Physiology. Renal Physiology 294 (2008), F1050–F1058.
188. Zager, R.A., Johnson, A.C., Lund, S., Hanson, S.Y., Abrass, C.K., Levosimendan protects against experimental endotoxemic acute renal failure. American Journal of Physiology. Renal Physiology 290 (2006), F1453–F1462.
189. Zanotti-Cavazzoni, S.L., Hollenberg, S.M., Cardiac dysfunction in severe sepsis and septic shock. Current Opinion in Critical Care 15 (2009), 392–397.
190. Zarbock, A., Abram, C.L., Hundt, M., Altman, A., Lowell, C.A., Ley, K., PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling. The Journal of Experimental Medicine 205 (2008), 2339–2347.
191. Zeni, F., Freeman, B., Natanson, C., Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Critical Care Medicine 25 (1997), 1095–1100.
192. Zhou, M., Simms, H.H., Wang, P., Adrenomedulin and adrenomedulin binding protein-1 attenuate vascular endothelial cell apoptosis in sepsis. Annals of Surgery 240 (2004), 321–330.
193. Zong, W., Qian, K., Xiong, J., Ma, K., Wang, A., Zou, Y., Curcumin alleviates lipopolysaccharide induced sepsis and liver failure by suppressing of oxidative stress-related inflammation via PI3K/AKT and NF-κB related signaling. Biomedicine & Pharmacotherapy 83 (2016), 302–313.